Immunocore

immunocore.com

Immunocore Holdings plc is a commercial-stage biotechnology company that has pioneered the world’s first approved T cell receptor (TCR) therapy. The company focuses on radically improving outcomes for patients with cancer, infectious diseases, and autoimmune diseases through its proprietary Imm TAX technology, which enables the development of bispecific therapies targeting a range of indications. With a diverse pipeline and a strong emphasis on transformative immunomodulating medicines, Immunocore is positioned as a leader in the immunotherapy space, leveraging its innovative platform to deliver significant patient benefits and drive growth in the biotechnology sector.